Biscayne Neurotherapeutics raises $3m for antiepileptic compound
The financing was led by the Global Health Sciences Fund of Quark Venture and GF Securities, along with Mesa Verde Venture Partners. Existing Biscayne Pharmaceuticals investors and new
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
The collaboration will combine Lundbeck's expertise in the treatment of psychiatric and neurological disorders with IBM's cognitive and knowledge-based analytics to foster the discovery and development of new
The project, entitled “Exploitation of transport mechanisms for novel Gram-negative antibiotic drug discovery”, will leverage Discuva’s proprietary SATIN technology to explore new biological targets and deliver novel drug
Connect Biopharmaceuticals, Ltd., a clinical-stage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and cancer, today announces the completion of a $20